Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berzosertib, Cisplatin, and Radiation Therapy in Locally Advanced HNSCC
NCT02567422Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2017
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of berzosertib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoints: Number of Participants Experiencing Grade 3, 4, and 5 Adverse Events at 6.5 years, Number of Participants Experiencing a Dose Limiting Toxicities at 10 weeks and 1 more. Started Apr 2017; status: active, not recruiting.
02
Drugs
berzosertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02567422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02567422.